

07|10|2022

Claire **HAWKSWORTH**, Colm **LEONARD**, Isabelle **TONGIO**, Betsy Wonderly **TRAINOR**, Dalia **DAWOUD**

REPORT of the Regulatory/HTA/Payer EAP

Session 5

This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 820755. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA and bioMérieux SA, Janssen Pharmaceutica NV, Accelerate Diagnostics S.L., Abbott, Bio-Rad Laboratories, BD Switzerland Sàrl, and The Wellcome Trust Limited.





UNIVERSITÀ
di VERONA



University Medical Center Groningen



RAMBAM
Health Care Campus



**UNIVERSIDAD
DE LA RIOJA**



NICE National Institute for
Health and Care Excellence

Gesundheit Österreich
GmbH



ESCMID EUROPEAN SOCIETY
OF CLINICAL MICROBIOLOGY
AND INFECTIOUS DISEASES



ERS EUROPEAN
RESPIRATORY
SOCIETY
every breath counts



ZonMw



Fifth EAP session

1.1. Meeting overview

The fifth session of the VALUE-Dx Expert Advisory Panel (EAP) was held virtually on the 07 October 2022. There were six members of the EAP.

1.2. Topics and themes discussed

1. VALUE-Dx Progress update

Progress VALUE-Dx to date including an update on the clinical trials and the key achievements to date.

2. Presentation from guest speaker

The National Institute for Health and Care Excellence (NICE) provided an overview of a new model for the evaluation and purchase of antimicrobials that is being piloted in England including the development and key success factors.

3. Feedback on recommendations for innovative fit for purpose pricing and funding models for CA-ARTI diagnostics:

- Subscription-based procurement models
- Using MEAT (Most Economically Advantageous Tender) criteria for awarding procurement bids
- Managed-entry agreements

4. Clinical Decision Support Systems (CDSS) and HTA approaches for these technologies

